Cogent Biosciences Announces Positive Updated Lead-in Data From Ongoing Phase 3 Peak Trial Evaluating Bezuclastinib in Combination With Sunitinib in Patients With Gastrointestinal Stromal Tumors (Gist) at Asco Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.